title: Oral administration of the Aureobasidium pullulans-derived β-glucan effectively prevents the development of high fat diet-induced fatty liver in mice.
abstract: Aureobasidium pullulans-derived β-glucan (AP-PG) consisting of a β-(1,3)-linked glucose main chain and β-(1,6)-linked glucose branches is taken as a supplement to improve health. This study demonstrates that oral administration of AP-PG is effective to prevent the development of high-fat diet (HFD)-induced fatty liver in mice. Here, C57BL/6N mice were fed with a normal diet or HFD, and AP-PG diluted in drinking water was administered orally. After 16 weeks, the serological analysis showed that HFD-induced high blood cholesterol and triglyceride levels were reduced by the oral administration of AP-PG. Further, HFD induced-fatty liver was significantly reduced by the oral administration of AP-PG. The triglyceride accumulation in the liver was also significantly reduced in mice administered AP-PG. Liver injury as indicated by an increase in serum alanine aminotransferase (ALT) in the HFD-fed mice was significantly reduced in the mice administered AP-PG orally, and the gene expression of cholesterol 7 alpha-hydroxylase (CYP7A1) which is known to be involved in cholesterol degradation in the liver was significantly increased in the AP-PG administered mice. These results suggest the possibility that the oral administration of AP-PG is effective to prevent the development of non-alcoholic fatty liver disease (NAFLD).
authors.affiliation: Aureo Science Co., Ltd., Sapporo, Hokkaido, Japan.
authors.forename: Shiho
authors.initials: S
authors.lastname: Aoki
authors.affiliation: 1] Aureo Science Co., Ltd., Sapporo, Hokkaido, Japan [2] Aureo Co., Ltd., Kimitsu, Chiba, Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Iwai
authors.affiliation: 1] Aureo Science Co., Ltd., Sapporo, Hokkaido, Japan [2] Aureo Co., Ltd., Kimitsu, Chiba, Japan.
authors.forename: Koji
authors.initials: K
authors.lastname: Kawata
authors.affiliation: Aureo Science Co., Ltd., Sapporo, Hokkaido, Japan.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Muramatsu
authors.affiliation: Aureo Co., Ltd., Kimitsu, Chiba, Japan.
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Uchiyama
authors.affiliation: Aureo Co., Ltd., Kimitsu, Chiba, Japan.
authors.forename: Mitsuyasu
authors.initials: M
authors.lastname: Okabe
authors.affiliation: Division of Molecular Immunology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Ikesue
authors.affiliation: Division of Molecular Immunology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.
authors.forename: Naoyoshi
authors.initials: N
authors.lastname: Maeda
authors.affiliation: 1] Division of Molecular Immunology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan [2] Department of Matrix Medicine, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.
authors.forename: Toshimitsu
authors.initials: T
authors.lastname: Uede
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001203:Ascomycota / Q000737:chemistry*; D059305:Diet, High-Fat; D005936:Glucans / Q000008:administration & dosage*; D051379:Mice; D008810:Mice, Inbred C57BL; D065626:Non-alcoholic Fatty Liver Disease / Q000209:etiology / Q000517:prevention & control*
chemical_list: D005936:Glucans